<div id="readability-page-1"><p>Vest Financial LLC lowered its holdings in  Elevance Health, Inc. (NYSE:ELV - Free Report) by 10.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 88,982 shares of the company's stock after selling 10,817 shares during the period. Vest Financial LLC's holdings in Elevance Health were worth $28,752,000 at the end of the most recent reporting period.</p><ul><li>This ETF Is Proof That the Healthcare Rebound Is Real</li></ul><p>Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Joel Isaacson &amp; Co. LLC boosted its stake in shares of  Elevance Health by 45.3% during the 3rd quarter. Joel Isaacson &amp; Co. LLC now owns 1,765 shares of the company's stock valued at $570,000 after buying an additional 550 shares during the last quarter.  Sage Mountain Advisors LLC raised its holdings in  Elevance Health by 18.2% in the third quarter. Sage Mountain Advisors LLC now owns 1,848 shares of the company's stock valued at $597,000 after acquiring an additional 285 shares in the last quarter.  Jackson Thornton Wealth Management LLC bought a new position in  Elevance Health during the 3rd quarter valued at $256,000.  Americana Partners LLC acquired a new position in  Elevance Health during the 3rd quarter worth $393,000.  Finally, Professional Advisory Services Inc. increased its position in shares of  Elevance Health by 1.6% in the 3rd quarter. Professional Advisory Services Inc. now owns 76,354 shares of the company's stock worth $24,672,000 after purchasing an additional 1,170 shares during the last quarter. 89.24% of the stock is currently owned by hedge funds and other institutional investors. </p><div><p><span></span><span>Get <strong>Elevance Health</strong> alerts:</span></p></div><h2>Wall Street Analysts Forecast Growth</h2><p>Several equities analysts have recently commented on the stock. Sanford C. Bernstein  reaffirmed an &#34;outperform&#34; rating and set a $431.00 price target on shares of Elevance Health in a research report on Tuesday, January 6th. Robert W. Baird increased their target price on Elevance Health from $297.00 to $340.00 and gave the stock a &#34;neutral&#34; rating in a report on Thursday, December 11th. Mizuho  set a $413.00 price target on Elevance Health in a report on Friday, January 9th. Bank of America upped their price target on Elevance Health from $330.00 to $370.00 and gave the company a &#34;neutral&#34; rating in a research report on Friday, October 10th. Finally, Wells Fargo &amp; Company lifted their price objective on shares of Elevance Health from $403.00 to $424.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, January 7th. Thirteen analysts have rated the stock with a Buy rating and twelve have issued  a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $400.85.</p><ul><li>Getting Defensive: 3 Dividend Payers Reporting Strong Q3 Earnings</li></ul><p><b>View Our Latest Analysis on Elevance Health</b></p><h2>Elevance Health Price Performance</h2><p>Shares of NYSE ELV opened at $368.27 on Wednesday. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The firm has a market capitalization of $81.84 billion, a PE ratio of 15.05, a P/E/G ratio of 1.93 and a beta of 0.51. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.56 and a quick ratio of 1.56. The business's fifty day moving average price is $346.57 and its two-hundred day moving average price is $328.18. </p><ul><li>Why Centene Stock Dropped 40% — And Whether It's a Buy Now</li></ul><p>Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings data on Tuesday, October 21st. The company reported $6.03 earnings per share for the quarter, topping analysts' consensus estimates of $5.03 by $1.00. The business had revenue of $50.09 billion for the quarter, compared to analysts' expectations of $49.26 billion. Elevance Health had a net margin of 2.84% and a return on equity of 16.17%. The company's revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter last year, the company earned $8.37 EPS.  On average, research analysts expect that  Elevance Health, Inc. will post 33.96 EPS for the current year. </p><h2>Elevance Health Profile</h2> (Free Report)<p>Elevance Health, Inc <span>NYSE: ELV<span></span></span> is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.  </p><p>Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Elevance Health</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>Do not delete, read immediately</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Executive Order 14330: Trump’s Biggest Yet</li></ul><p><strong>Want to see what other hedge funds are holding ELV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMVg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Elevance Health Right Now?</h2><p>Before you consider Elevance Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.</p><p>While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Vest Financial LLC has reduced its holdings in Elevance Health, Inc. (NYSE:ELV) by 10.8% in Q3, now owning 88,982 shares after selling 10,817 shares. The value of these holdings is approximately $28.75 million. Other institutional investors have also adjusted their positions, with notable increases from Joel Isaacson & Co. LLC and Sage Mountain Advisors LLC. Analysts maintain a "Moderate Buy" rating for Elevance Health, with an average target price of $400.85. The stock opened at $368.27, with a market cap of $81.84 billion and a PE ratio of 15.05.</p>

Market Beat

Vest Financial LLC Reduces Position in Elevance Health, Inc. $ELV